EcoDrugPlus

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSOMEG00000016453
Gene Symbol: MTOR
1 Cross references
215 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSOMEG00000002838
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOMEG00000001066
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSOMEG00000001342
Gene Symbol: LOC112151354
2 Cross references
215 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSOMEG00000002302
Gene Symbol: MTNR1A
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSOMEG00000010750
Gene Symbol: MME
4 Cross references
233 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSOMEG00000002258
Gene Symbol: LOC112144978
3 Cross references
206 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSOMEG00000007328
Gene Symbol: LOC112151932
3 Cross references
215 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSOMEG00000002985
Gene Symbol: METAP2
4 Cross references
220 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSOMEG00000002899
Gene Symbol: LOC112154425
2 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSOMEG00000009208
Gene Symbol: MAPK1
3 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSOMEG00000018584
Gene Symbol: LOC112146278
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).